Inventor
MASSARE MICHAEL J
US20 patents
Patents
20 patentsUS10953089B1Mar 23, 2021
Coronavirus vaccine formulations
NOVAVAX INC99 citations98
US10022437B2Jul 17, 2018
Modified RSV F proteins and methods of their use
NOVAVAX INC22 citations94
US10426829B2Oct 1, 2019
Vaccine compositions having improved stability and immunogenicity
NOVAVAX INC17 citations93
US9675685B2Jun 13, 2017
Modified RSV F proteins and methods of their use
NOVAVAX INC11 citations92
US11541112B2Jan 3, 2023
Coronavirus vaccine formulations
NOVAVAX INC5 citations85
US11253586B2Feb 22, 2022
Coronavirus vaccine formulations
NOVAVAX INC4 citations84
US11253585B2Feb 22, 2022
Vaccine compositions having improved stability and immunogenicity
NOVAVAX INC8 citations84
US11052146B2Jul 6, 2021
Modified RSV F proteins and methods of their use
NOVAVAX INC3 citations84
US9731000B2Aug 15, 2017
Modified RSV F proteins and methods of their use
NOVAVAX INC7 citations84
US9717786B2Aug 1, 2017
Modified RSV F proteins and methods of their use
NOVAVAX INC7 citations84
US12357684B2Jul 15, 2025
Modified RSV F proteins and methods of their use
NOVAVAX INC2 citations74
US11896664B2Feb 13, 2024
Corona virus vaccine formulations
NOVAVAX INC2 citations73
US11446374B2Sep 20, 2022
Modified RSV F proteins and methods of their use
NOVAVAX INC5 citations73
US11364294B2Jun 21, 2022
Vaccine compositions having improved stability and immunogenicity
NOVAVAX INC2 citations71
US12491241B2Dec 9, 2025
Coronavirus vaccine formulations
NOVAVAX INC0 citations62
US12472246B2Nov 18, 2025
Coronavirus vaccine formulations
NOVAVAX INC0 citations62
US12257297B2Mar 25, 2025
Vaccine compositions having improved stability and immunogenicity
NOVAVAX INC0 citations61
US9951317B2Apr 24, 2018
Highly efficient influenza matrix (M1) proteins
NOVAVAX INC1 citations60
US12083228B2Sep 10, 2024
Methods and compositions for treating respiratory disease
NOVAVAX INC1 citations59
US10544399B2Jan 28, 2020
Highly efficient influenza matrix (M1) proteins
NOVAVAX INC0 citations49